البلد: الولايات المتحدة
اللغة: الإنجليزية
المصدر: NLM (National Library of Medicine)
LEVOTHYROXINE SODIUM (UNII: 9J765S329G) (LEVOTHYROXINE - UNII:Q51BO43MG4)
Mylan Institutional Inc.
LEVOTHYROXINE SODIUM
LEVOTHYROXINE SODIUM ANHYDROUS 25 ug
ORAL
PRESCRIPTION DRUG
Hypothyroidism: Levothyroxine sodium tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression: Levothyroxine sodium tablets are indicated as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer. Limitations of Use: - Levothyroxine sodium tablets are not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients as there are no clinical benefits and overtreatment with levothyroxine sodium tablets may induce hyperthyroidism [see Warnings and Precautions (5.4)]. - Levothyroxine sodium tablets are not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis. Levothyroxine sodium tablets are contraindicated in patients with uncorrected adrenal insufficie
Levothyroxine Sodium Tablets, USP are available containing 25 mcg, 50 mcg, 75 mcg, 100 mcg, 125 mcg or 150 mcg of levothyroxine sodium, USP. They are available as follows: The 25 mcg tablets are orange, capsule-shaped, scored tablets debossed with L to the left of the score and 4 to the right of the score on one side of the tablet and M on the other side. NDC 51079-444-20 – Unit dose blister packages of 100 (10 cards of 10 tablets each). The 50 mcg tablets are white, capsule-shaped, scored tablets debossed with L to the left of the score and 5 to the right of the score on one side of the tablet and M on the other side. NDC 51079-440-20 – Unit dose blister packages of 100 (10 cards of 10 tablets each). The 75 mcg tablets are violet, capsule-shaped, scored tablets debossed with L to the left of the score and 6 to the right of the score on one side of the tablet and M on the other side. NDC 51079-441-20 – Unit dose blister packages of 100 (10 cards of 10 tablets each). The 100 mcg tablets are yellow, capsule-shaped, scored tablets debossed with L to the left of the score and 8 to the right of the score on one side of the tablet and M on the other side. NDC 51079-442-20 – Unit dose blister packages of 100 (10 cards of 10 tablets each). The 125 mcg tablets are gray, capsule-shaped, scored tablets debossed with L to the left of the score and 10 to the right of the score on one side of the tablet and M on the other side. NDC 51079-443-20 – Unit dose blister packages of 100 (10 cards of 10 tablets each). The 150 mcg tablets are blue, capsule-shaped, scored tablets debossed with L to the left of the score and 11 to the right of the score on one side of the tablet and M on the other side. NDC 51079-445-20 – Unit dose blister packages of 100 (10 cards of 10 tablets each). Storage Conditions: Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Protect from light and moisture.
Abbreviated New Drug Application
LEVOTHYROXINE SODIUM- LEVOTHYROXINE SODIUM TABLET MYLAN INSTITUTIONAL INC. ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE LEVOTHYROXINE SODIUM TABLETS SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR LEVOTHYROXINE SODIUM TABLETS. LEVOTHYROXINE SODIUM TABLETS, FOR ORAL USE INITIAL U.S. APPROVAL: 2002 WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS _SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING_ THYROID HORMONES, INCLUDING LEVOTHYROXINE SODIUM TABLETS SHOULD NOT BE USED FOR THE TREATMENT OF OBESITY OR FOR WEIGHT LOSS. DOSES BEYOND THE RANGE OF DAILY HORMONAL REQUIREMENTS MAY PRODUCE SERIOUS OR EVEN LIFE THREATENING MANIFESTATIONS OF TOXICITY ( 6, 10). INDICATIONS AND USAGE Levothyroxine sodium tablets are levothyroxine sodium (T4) indicated for: Hypothyroidism: As replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. ( 1) Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression: As an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer. ( 1) Limitations of Use: Not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine- sufficient patients. Not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis. DOSAGE AND ADMINISTRATION Administer once daily, preferably on an empty stomach, one-half to one hour before breakfast. ( 2.1) Administer at least 4 hours before or after drugs that are known to interfere with absorption. ( 2.1) Evaluate the need for dose adjustments when regularly administering within one hour of certain foods that may affect absorption. ( 2.1) Starting dose depends on a variety of factors, including age, body weight, cardiovascular status, and concomitant medications. Peak therapeutic effect may not be attained for 4-6 weeks. ( 2.2) See full prescribing information for do اقرأ الوثيقة كاملة